AlphAIAlphAI — Financial news for AI agents
SEC EDGARJUN 21 min read$QTTB

ORBIMED ADVISORS LLC purchased $15.0M of QTTB (indirect holdings)

ORBIMED ADVISORS LLC purchased 1,875,000 indirectly-held shares of Q32 Bio Inc. (QTTB) at $8.00 ($15.00M total) across 2 trades on 2026-05-28. Filed jointly with OrbiMed Capital GP VII LLC (Director) and OrbiMed Genesis GP LLC (Director).

Original reporting
SEC EDGAR · ORBIMED ADVISORS LLC, OrbiMed Capital GP VII LLC, OrbiMed Genesis GP LLC
Published Jun 2, 2026, 1:13 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 28, 2026, 3:42 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$QTTB
Bullish
high confidence
Mentioned
$QTTB
Relevance
8/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$QTTBBullishMed
01

Why it matters

The sizable buy may be interpreted as a vote of confidence, potentially supporting the stock price in the short term.

02

Market read

First‑report insider purchase provides fresh material for traders evaluating Q32 Bio.

03

What to watch

Potential upcoming clinical data releases or financing needs not disclosed.

Relevance 8/10Novelty 7/10Timing: filing day today

Background

Form 4 filing from SEC reveals an insider purchase by OrbiMed Advisors, a director and 10% owner of Q32 Bio.

Company-level read

Ticker impact

$QTTBBullishHigh confidence
Context

OrbiMed Advisors bought 1,875,000 shares of Q32 Bio at $8 each, a $15 M open‑market purchase disclosed on Form 4.

Expected impact

potential upward pressure as the market prices in insider confidence

Evidence & confidence

The $15 M stake by a director and 10% owner is a material insider buy, likely viewed as a bullish signal.

Market effects

Sector

Biotech sector may see modest uplift as insider buying signals pipeline confidence.

Regional

U.S. biotech investors could react positively, limited broader market effect.

Global

Minimal global impact beyond niche biotech investors.

Counterpoint

What could challenge this read

The purchase could be a defensive move to maintain control rather than a growth bet.

Key entities

  • company
    Q32 Bio Inc.

    Biotech firm developing therapies, ticker QTTB.

  • insider
    OrbiMed Advisors LLC

    Director and 10% owner of Q32 Bio.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

QTTB insider trading history →

Related articles

SEP 30
$QTTBHighAI 8/10

Why is Q32 Bio stock surging today?

Q32 Bio (QTTB) stock surged 20.8% in pre-market trading after releasing Phase 2a results for bempikibart at the EADV Congress. The data showed 36-week efficacy and 16-week off-drug findings for alopecia areata. Analysts initiated coverage with Buy ratings and price targets of $29 (Jefferies) and $38 (Clear Street), citing high revenue potential and favorable safety profile. The broader market had a mild positive impact.

investing.com2 min
SEP 30
$QTTBMedAI 8/10

Q32 Bio Presents Results from Part B of the SIGNAL-AA Clinical Trial of Bempikibart in Alopecia Areata in a Late-Breaker at the European Academy of…

Q32 Bio Inc. (QTTB) filed an SEC Form 8-K — Other Events. Exhibit 99.1 Q32 Bio Presents Results from Part B of the SIGNAL-AA Clinical Trial of Bempikibart in Alopecia Areata in a Late-Breaker at the European Academy of Dermatology and Venereology Congress 2026 — Clinically meaningful efficacy data observed on primary and key secondary e

SEC EDGAR 8-K2 min
SEP 30
$QTTBHighAI 8/10

Q32 Bio Presents Results from Part B of the SIGNAL-AA Clinical Trial of Bempikibart in Alopecia Areata in a Late-Breaker at the European Academy of Dermatology and Venereology Congress 2026

Q32 Bio (QTTB) presented 36-week results from its SIGNAL-AA Phase 2a trial of bempikibart for alopecia areata at EADV 2026. The drug showed clinically meaningful efficacy, with a 35.3% mean reduction in SALT scores. 40% of patients achieved SALT-20 response. The 16-week off-drug period showed durable responses, with 44% maintaining SALT-20. Q32 Bio plans to advance a registration-directed program in 2027.

prnewswire.com2 min
SEP 14
$QTTBMedAI 8/10

Q32 Bio Appoints New CMO And CDO To Support Advancement Of Bempikibart

Q32 Bio Inc. (QTTB) appointed José Trevejo, M.D., Ph.D., as Chief Medical Officer and Ellie Hershberger, Pharm.D., as Chief Development Officer. The company is advancing Bempikibart into late-stage development for alopecia areata, with a registration-directed program planned for 2027. Bempikibart showed promising results in early trials, including hair regrowth and a well-tolerated safety profile. QTTB's stock is currently trading at $11.14, up 0.39%.

rttnews.com2 min
SEP 5
$AAPLHighAI 8/10

Why Did AAPL, QTTB, CSX Stocks Surge To 52-Week Highs Today?

Apple (AAPL), Q32 Bio (QTTB), and CSX Corp. (CSX) reached 52-week highs. AAPL rose 0.6% to $323.45; Citi raised its target to $365. QTTB surged 90% after positive clinical data; Wells Fargo upgraded it to 'Overweight' with a $66 target. CSX gained 0.4% to $49.90; Raymond James lifted its target to $56. Year-to-date gains: AAPL +16%, CSX +36%, QTTB +543%.

stocktwits.com2 min